Risk-based Monitoring Software Market to Reflect Impressive Growth in Healthcare
Posted by HealthcareNews on June 1st, 2020
Risk Based Monitoring (RBM) is a clinical trial-monitoring technique that fulfills regulatory requirements but moves away from 100% source data verification (SDV) of patient data. It employs various tools, platforms and dashboards to identify signals, which indicate potential issues with (for example) trial conduct, safety, data integrity, compliance and enrolment.Also See: Software Market, Risk Based, Based Monitoring, Clinical Trials, Software, Market, Clinical
What The Market Looks Like?
The risk-based monitoring (RBM) software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3%.
Based on the component, the RBM software market is segmented into Software and Services. In 2020, the software segment is expected to command the largest share of the RBM software market. The large share of this segment can be attributed to can be attributed to the increasing R&D expenditure in the life science and clinical research industries, an increasing number of clinical trials, and rising customer base.
The pharmaceutical and biopharmaceutical companies segment is expected to command the largest share of the RBM software market. The increasing R&D expenditure of pharmaceutical and biopharmaceutical companies is the major factor driving the growth of this end-user segment.
Download PDF Brochure:
Key Factors Driving Growth in RBM Software Market:
1. Cost and time efficiency of RBM solutions
2. Rising number of clinical trials
3. Increasing government funding and grants to support clinical trials
4. Increased outsourcing of clinical trial processes to CROs
Geographical Growth Analysis of Risk-based Monitoring Software Market:
The Asia Pacific market is expected to grow at the highest CAGR in the forecast period. This growth can be attributed to increasing government funding to support clinical trials, the presence of less stringent regulatory guidelines as compared to developed nations, a large patient base, low operating costs for conducting clinical trials, shortage of trial volunteers in Europe and North America, and the growing number of pharmaceutical companies and CROs in the region.